• Home
  • History
    • Introduction
    • The Aspirin Story
    • Timeline
    • Chemistry
  • Advisory Board
  • Awards
  • Conferences
  • Scientific Information
    • Guidelines
    • Disease Prevention
    • Aspirin Summaries
    • Aspirin Matters
  • News
  • Contact
Menu
  • Home
  • History
    • Introduction
    • The Aspirin Story
    • Timeline
    • Chemistry
  • Advisory Board
  • Awards
  • Conferences
  • Scientific Information
    • Guidelines
    • Disease Prevention
    • Aspirin Summaries
    • Aspirin Matters
  • News
  • Contact
Search
Close
All ASPIRIN SUMMARIES

ISSUE 2021 (13)

Aspirin summaries: Aspirin and peripheral artery disease (PAD)

Table of Contents

Download PDF

Aspirin summaries: Aspirin and peripheral artery disease (PAD)

Peripheral artery disease (PAD), a form of cardiovascular disease (CVD) is caused by fatty deposits (atheroma) building up in the arteries and restricting the blood flow to the legs1. Often people may have no symptoms, but some develop leg pain when they are walking which is relived by rest1. This is called intermittent claudication and can range in severity. Other symptoms include, hair loss on legs and feet, numbness or weakness in the limbs, slow growing or brittle toenails, ulcers, change in skin colour or texture on the legs e.g. pale or blue and shiny skin, muscle wasting in the legs and erectile dysfunction1. A serious complication, critical limb ischaemia, can develop from PAD if the circulation to the legs is severely impaired1. Having PAD is a sign that other forms of cardiovascular disease may exist within the body and thus means people with PAD are more likely to experience a cardiovascular event such as coronary heart disease (CHD), stroke, myocardial infarction (MI) or angina1.

Reduced exercise and quality of life can result from symptoms of PAD as well as tissue loss from its complications2. Treatment includes lifestyle changes such as regular exercise, smoking cessation, healthy diet, healthy weight and reducing alcohol1. Medication to help manage the underlying causes of PAD and to reduce overall CVD risk includes statins, drugs for high blood pressure, medicines to thin the blood such as low-dose aspirin, clopidogrel and rivaroxaban1. Naftidrofuryl oxalate is sometimes used to treat leg pain that is triggered by walking1. Surgical revascularisation techniques are used to help improve blood flow within the legs1.

NICE 20203 guidelines recommend rivaroxaban plus aspirin for the prevention of atherothrombotic events in adults with coronary artery disease or symptomatic PAD if they are at high risk of ischaemic events. NICE 20203 defines people at high risk of ischemic events as aged 65 years or over or atherosclerosis in at least two or more vascular areas (coronary, cerebrovascular or PAD) or two or more risk factors (current smoking, diabetes, kidney dysfunction, heart failure, previous vascular stroke). A risk benefit discussion with the patient, explaining about bleeding risk and the potential benefits from treatment, should be carried out before commencing therapy.  The American College of Cardiology (ACC) 2018 guidelines4 recommend that people with symptomatic PAD are treated with a single antiplatelet such as aspirin or clopidogrel to reduce cardiovascular risk. The ACC4 also recommend those undergoing revascularization for PAD receive lifelong antithrombotic therapy and that aspirin, clopidogrel and rivaroxaban plus aspirin are all suitable strategies. European Society of Cardiology 2017 guidelines for PAD recommend antiplatelet therapy for symptomatic PAD in order to reduce secondary cardiovascular events5.

The following summary focuses on recent articles exploring the role of low-dose aspirin for the management of PAD.

References:

1. NHS UK.Overview Peripheral arterial disease (PAD) reviewed 31/10/2019 accessed 26/01/2021@ https://www.nhs.uk/conditions/peripheral-arterial-dsiease-pad/
2. HiattWR, BonacaMP, PatelMR et al. Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization impact of concomitant clopidogrel on efficacy and safety. Circulation. 2020; December 8; 142 (23): 2219-2230. https://doi.org/10.1161/CIRCULATIONAHA.120.050465.
3. NICE Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease. TA 607. 17October 2019. Accessed 30/01/21@ https://www.nice.org.uk/guidelines/ta607/chapter/1-Recommendatios
4. Hussain MA, Al-Omran, CreagerMA et al. Antithrombotic therapy for peripheral artery disease: Recent Advances. 2018; 71:2450-2467. Accessed 30/01/21@ https://www.acc.org/latest-in-cardiology/ten-points-to- remember/2018/05/22/14/46/antithrombotic-therapy-for-peripheral-artery-disease
5. Aboyans V, Ricco J-B, Bartelink M-L et al. 2017 ESCGuidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). EuropeanHeart Journal.39:763-821. doi:10.1093/eurheart/ehx095

 

The combination of aspirin and rivaroxaban results in significantly fewer cardiovascular and leg complications following lower-limb revascularization when compared with aspirin alone.

VOYAGER PAD (Vascular Outcomes Study of ASA Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD), is a phase 3, international double-blind, placebo-controlled trial of low-dose aspirin plus or minus rivaroxaban 2.5mg twice daily for people with symptomatic PAD requiring lower extremity revascularization (LER). Primary outcomes were a composite of acute limb ischemia, major amputation due to a vascular cause, MI, ischemic stroke or cardiovascular death. Bleeding risks were also assessed using the major bleeding category described by the Thrombolysis in Myocardial Infarction (TIMI) classification. The International Society on Thrombosis and Haemostasis (ISTH) major bleeding definition was a secondary safety outcome.

The study recruited 6564 patients, 50 years and older, who had undergone successful revascularization within the previous 10 days for symptomatic PAD.  Study participants were randomly assigned to receive either aspirin 100mg daily plus rivaroxaban 2.5mg twice daily (3286 people) or aspirin 100mg plus placebo (3278). Primary outcomes occurred in 508 people in the rivaroxaban group and 584 in the placebo group with Kaplan-Meir estimates of 3-year incidence at 17.3% for the active arm and 19.9% for placebo (hazard ratio, 0.85, 95% CI, 0.76 to 0.96; P=0.009).Major bleeding defined by TIMI classification was seen in 62 patients (2.65%) in the low-dose aspirin plus rivaroxaban arm and 44 patients (1.87%) in the low-dose aspirin plus placebo group (hazard ratio, 1.43; 95% CI, 0.97 to 2.10; P=0.07). The is the major bleeding definition arose in 140 (5.94%) of the rivaroxaban and 100 (4.06%) of the placebo group (hazard ratio, 1.42; 95% CI, 1.10 to 1.84; P=0.007).

The results showed a significantly lower incidence of acute, limb ischemia, major amputation, MI, ischemic stroke or cardiovascular death when rivaroxaban is added to a background of low-dose aspirin therapy. Close to 1/5 of the placebo group experienced a major limb or cardiovascular adverse event and these were reduced by approximately 15% with the addition of rivaroxaban 2.5mg twice daily to a background of low- dose aspirin therapy. Adverse TIMI major bleeding was not significantly different between the two group but is the major bleeding events were significantly higher in the group taking rivaroxaban and aspirin.

For further information please see:

BonacaMP, Bauersachs RM, Anand SS et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl JMed. 2020; 382:1994-2004. DOI: 10.1056/NEJMoa2000052

 

A short course of clopidogrel can be used in addition to low-dose aspirin and rivaroxaban to improve vascular outcomes for people undergoing endovascular or surgical limb revascularization for PAD – results from the VOYAGER PAD trial.

VOYAGER PAD, as described above also allowed for the addition of clopidogrel by the investigator for up to six months after revascularization.

Around half of the 3313 patients randomised in VOYAGER PAD were given clopidogrel for an average of 4 weeks.  The results showed that low-dose aspirin and rivaroxaban reduced the risk of cardiovascular and limb events and the efficacy and safety of this regimen was not affected when clopidogrel was used for less than 30 days.  Using clopidogrel for more than 30 days was linked to greater bleeding risk.

Clopidogrel was not randomised in this study but does have the advantage of reflecting real world usage.  Dual antiplatelet with aspirin and clopidogrel is often used after revascularization for PAD , with the intention of reducing vascular events and increasing the success of the procedure even though there is a lack of evidence to support this.

The authors conclude:

“These data support a primary treatment strategy of rivaroxaban plus aspirin after technically successful LER with adequate hemostasis regardless of whether clopidogrel is used as a short-
term procedural adjunct.  If concomitant clopidogrel is also used, with a goal of reducing procedural complications in the short term, a duration of 30 days versus longer durations is associated with less bleeding.”

For further information please see:

HiattWR, BonacaMP, PatelMR et al. Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization impact of concomitant clopidogrel on efficacy and safety. Circulation. 2020; December 8; 142 (23): 2219-2230. https://doi.org/10.1161/CIRCULATIONAHA.120.050465

 

The COMPASS Trial reports how a combination of low- dose aspirin and rivaroxaban significantly lowers the incidence of major limb adverse events in people with PAD.

The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) was a randomized, double-blind placebo-controlled study within which the role of low-dose aspirin and rivaroxaban versus low-dose aspirin alone was investigated for people with PAD in order to understand the impact of this on the incidence of major limb adverse events (MALE) and peripheral vascular interventions and outcomes.  Patients were followed up for a median of 21months.

The outcomes of 6391 patients with lower extremity PAD enrolled in COMPASS were examined and the results showed 128 people with an incidence of MALE.  After a MALE there was a 1-year cumulative risk of further hospitalization of 61.5%, a 20.5% risk of vascular amputation, an 8.3% risk of death and a 3.7% risk of a major adverse cardiovascular event (MACE).  A combination of rivaroxaban (2.5mg twice daily) in addition to low-dose (100mg daily) aspirin reduced the incidence of MALE by 43% (p=0.01), vascular amputations by 58% (p=0.01), peripheral vascular interventions by 24% (p=0.03) and all peripheral outcomes by 24% (p=0.02%) when compared with low- dose aspirin alone.

The authors explain that major limb adverse events in people with stable PAD carries a ‘dire prognosis’ which means prevention is crucial and that the combination of low-dose aspirin and rivaroxaban is an important way to help improve outcomes.

The authors conclude:

“Given the effectiveness of low- dose rivaroxaban and aspirin, this combination therapy should be considered for patients with PAD to prevent MALE and to reduce peripheral vascular interventions.’”

For further information please see:

Anand SS, Caron FC, Eikelboom JW et al.Major adverse limb events andmortality in patients with peripheral artery disease. Journal ofThe American College of Cardiology. 2018, May 22; 71(20) : 2306-2315. https://doi.org/10.1016/j.jacc.2018.03.008

 

Prognostic vascular risk and response to low-dose aspirin and rivaroxaban in people with symptomatic lower limb PAD.

This secondary analysis of the COMPASS trial sought to understand vascular risk features that could help predict response to low-dose aspirin and rivaroxaban therapy in patients with symptomatic lower limb PAD.

The researchers found that the risk ofmajor vascular events exceeded 10% over 30months in people with the following risk factors:

• Pervious peripheral revascularization
• Previous amputation
• Fontaine III [rest pain] or IV [ulcers or gangrene]symptoms
• Kidney dysfunction
• Heart failure
• Diabetes
• Polyvascular disease

They found that in this high-risk patient group there was an estimated 4.2% (95% CI, 1.9%-6.2%) absolute risk reduction inmajor vascular events when the of low-dose aspirin and was used in
comparison to low-dose aspirin alone.

The estimated absolute risk ofmajor bleeding events was higher with the combination therapy group (2.0% [95% CI, 0.5%-3.9%]) but in the high-risk group identified above the estimated absolute risk of fatal or critical organ bleeding was low (0.4% [95% CI, 0.2%- 1.8%]).The researchers predicted the net clinical benefit was 3.2% (95% CI, 0.6%-5.3%).

The authors conclude:

“For these patients, treatment with rivaroxaban and aspirin in combination compared with aspirin alone led to a large absolute reduction in vascular risk.”

For further information please see:

Kaplovitch E, Eikelboom JW, Dyal L et al. Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease. A Sub analysis of the COMPASS randomized clinical trial. JAMA Cardiol. 2021.6(1):21-29.doi:10.1001/jamacardio.2020.4390

 

Understanding bleeding risk with low-dose aspirin and rivaroxaban in coronary or peripheral artery disease.

Whilst the combination of aspirin 100mg once daily with rivaroxaban 2.5mg twice daily reduces cardiovascular events and mortality it is known to increase bleeding risk.

Eikelboom et al 2019, used data from the COMPASS trail in order to explore the bleeding risk from combination therapy compared with aspirin therapy alone in order to gain a better understanding of site, severity, timing and management.

The authors found that most of the increase in bleeding side effects when low-dose aspirin is combined with low-dose rivaroxaban is from the gastrointestinal tract, is mild to moderate, did not require a blood transfusion and occurred within the first year of starting treatment. The benefit in terms of reduced cardiovascular risk continued after this first year and thus a net clinical benefit accumulates with time.

For further information please see:

Eikelboom JW, Bosch JJ, Connolly SJ et al.Major bleeding in patients with coronary or peripheral artery disease treated with rivaroxaban plus aspirin. Journal ofThe America College of Cardiology. 2019, Sept 24; 74 (12): 1519-28.https://doi.org/10.1016/j.jacc.2019.07.065

 

Low-dose aspirin plus rivaroxaban found to be cost effective for targeted groups of patients when compared with single antiplatelet therapy.

This study used a state transition model to compare dual pathway inhibition (DPI) with solo antiplatelet therapy (using aspirin in coronary artery disease and clopidogrel in peripheral artery disease).

They found the dual pathway approach of low-dose aspirin and rivaroxaban for the lifelong preventative management of coronary artery disease and peripheral artery disease in those at risk of cardiovascular events only improved health outcomes but was also cost effective compared to single antiplatelet treatment especially in those with comorbidities.  However, in patients over 75 years and in people with carotid artery disease the dual pathway approach was not found to be cost effective.

The author concludes:

“The considerable economic impact of DPI may warrant a targeted approach. Further research is needed to address the long-term effectiveness of DPI and the effectiveness of clopidogrel for PAD.”

For further information please see:

Petersohn S, Pouwels X, Ramaekers B et al. Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study. European Journal of Preventative Cardiology. 2020. 27(13):1354-1365. Doi:10.1177/2047487320913380

 

Disclaimers:

• The information, views and opinions expressed are not endorsed or approved bymembers ofThe Scientific Advisory Board unless otherwise stated.
• The Information section is compiled using current published information at the time of writing and whilst every effort has been made to avoid errors, professional clinical judgement is required to interpret the information given.  The information given is referenced clearly for further analysis as required.
• Every effort is made by the International Aspirin Foundation to see that no misleading or inaccurate data, statement or opinion appear. The International Aspirin Foundation cannot be held responsible for any errors or for any consequences arising from the use of the information.
• The International Aspirin Foundation, its associates and The Scientific Advisory Board accept no liability whatsoever for the consequences of any such inaccurate or misleading data, information, opinion or statement.
• Any information involving drug usage, should only be followed in conjunction with the drug manufacturer’s own published literature in their own country.
• Medical sciences evolve on a continual basis and therefore independent verification of the content should be made.
• The information, views, opinions and any other material provided should not be relied upon as a substitute to professional medical advice in relation to any medical condition. The International Aspirin Foundation, its associates and The Scientific Advisory Board accept no liability whatsoever for any consequences arising from any reliance placed on such information, views, opinions and other materials in lieu of professional medical advice.

 

 

Back to top

SHARE THIS ARTICLE

Facebook
Twitter
LinkedIn
2021 02 24 17 12 40 Pdf Architect 7 → Aspirin Summaries 13 2021
Download the full summary as a PDF document.
Download PDF

Connect with us

Sign up to be part of the aspirin community and be the first to receive latest information.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Have something to say about aspirin?

Contact Us Here
Footer Logo
  • Terms & Conditions
  • Branding Guidelines
  • Privacy
  • Cookie Policy
  • Disclaimer
  • Terms & Conditions
  • Branding Guidelines
  • Privacy
  • Cookie Policy
  • Disclaimer
TwitterLinkedin

Copyright © 2020 Aspirin Foundation

Website by mtc.

Have something to say about aspirin?

Please fill in the form below and we will contact you with further information.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Djp

Daniel José Piñeiro

ASSOCIATE
Name
Daniel José Piñeiro
Academic Affiliations:
Full Professor of Medicine, Universidad de Buenos Aires, Argentina Trustee, Board of Trustees, American College of Cardiology
Professional Setting:
My academic experience includes more than 40 years as a practicing medical doctor, teacher, and researcher. I have fulfilled these appointments in settings of vital social engagement and impact, most notably at the Hospital de Clínicas “José de San Martín” of the Universidad de Buenos Aires, a public hospital with high academic recognition. Additionally, I currently hold the position of Full Professor of Medicine at that same University.
Academic Activities:
  • International Meetings Participations: 180
  • Books-Editor: 1
  • Books Chapters: 39
  • Refereed Full Articles: 118 (listed in Pubmed: 29)
  • Refereed Abstracts: 221
  • Editorial Boards: 10
Profesional Associations:
  • 2005 President, Sociedad Argentina de Cardiología.
  • 2011-2013 President, Inter-American Society of Cardiology.
  • 2011-2013 Member (ex-officio), Board of Directors, World Heart Federation
  • 2017-2018 Member (at large), Board of Directors, World Heart Federation
  • 2018-2021 Trustee, Board of Trustees, American College of Cardiology
Return to Scientific Advisory Board
Chia

John Chia

Name
John Chia MBBS (Spore), MRCP (UK), FAMS (Spore)
Academic Affiliations:

Adjunct Associate Professor DUKE-NUS Graduate Medical School,
Consultant Oncologist Curie Oncology Singapore,
Visiting Consultant National Cancer Centre Singapore.

Discipline:

Medical Oncology

Scientific Interests:
  • Aspirin as adjuvant therapy in established cancers
  • Adoptive T cell therapy and Dendritic cell vaccines in the treatment of solid tumors
  • Clinical Trial Design and Management
Declaration of Conflicts of Interest:

In the past 3 years, I have received consultant fees from Tessa Therapeutics, Aslan Pharmaceuticals, Novartis, and AstraZeneca.

I received grant support for investigator-initiated research from:

  • National Medical Research Council Singapore
  • Bayer AG

I hold shares in:  Roche, BMS, AstraZeneca, Incyte, Teva Pharmaceuticals, Trillium Therapeutics, Compugen, Arrowhead pharmaceuticals, Emergex, QuantumDx and Halozyme Therapeutics

Return to Scientific Advisory Board
Badimon

Lina Badimon

Name
Lina Badimon BSc, PharmD, PhD, FESC, FAHA
Academic Affiliations:
Director of the Cardiovascular Science Program (ICCC) at the Hospital Santa Creu and San Pau, IIB-Sant Pau; CIBER CV. Director of the Cardiovascular Research Chair of the Autonomous University of Barcelona and Director of the UNESCO Chair in Biomedical Sciences Training and Research.
Discipline:
Pharmacology, Cardiovascular Disease
Scientific Interests:
Cardio-metabolic diseases, thrombosis, atherosclerosis and ischemic heart disease
Declaration of Conflicts of Interest:

I received consultant and speakers fees from Amgen, AstraZeneca, Bayer, Lilly and Sanofi.

    Return to Scientific Advisory Board
    Ge

    Junbo Ge

    Name

    Junbo Ge

    Ge Junbo, male, was born in Wulian, Shandong province on Nov. 8, 1962. He is the member of Chinese Academy of Sciences, professor and doctoral supervisor. He received his doctor’s degree of Medicine from German Mayence University in 1993 and now works as the director for Shanghai Institute of Cardiovascular Disease and the Center for Stem Cells and Tissue Engineering, Fudan University. He is also the designate chairman of the Cardiovascular Disease Branch of Chinese Medical Association, council member of the Cardiovascular Angiography and Interventions Association, international consultant of the American Heart Association. In Dec. 2013, he was appointed as the vice president of Tongji University.

    Prof. Ge has been engaged in clinical and scientific research work of cardiovascular disease since 1987, and his research area covers the pathogenesis of coronary heart disease, early diagnosis and treatment plan optimization.

    Return to Scientific Advisory Board
    Langley

    Ruth Langley

    Name
    Ruth Langley PhD, FRCP
    Academic Affiliations:
    Professor of Oncology and Clinical Trials, MRC Programme Leader and Chair of the Cancer Group, MRC Clinical Trials Unit at UCL, honorary consultant in medical oncology at the Brighton and Sussex University Hospital.
    Discipline:
    Medical oncologist; trialist
    Scientific Interests:
    • Aspirin
    • Gastro-oesophageal malignancy
    • Transdermal oestrogen in the treatment of prostate cancer
    • Trials methodology
    Declaration of Conflicts of Interest:
    Has received honorarium from Bayer
    Return to Scientific Advisory Board
    Chan

    Andrew T Chan

    Name
    Andrew T. Chan MD, MPH
    Academic Affiliations:
    Chief, Clinical and Translational Epidemiology Unit, Vice Chair, Division of Gastroenterology, Massachusetts General Hospital, Boston, Co-leader, Cancer Epidemiology Program, Dana-Farber/Harvard Cancer Center, Boston.
    Discipline:
    Gastroenterology
    Scientific Interests:
    • The role of aspirin in the prevention of colorectal cancer and other cancers
    • The role of the gut microbiome in colorectal cancer and other chronic gastrointestinal diseases, including inflammatory bowel disease and diverticulitis
    • The role of diet and lifestyle in colorectal cancer and other chronic gastrointestinal cancers
    Declaration of Conflicts of Interest:

    AACR Honors Dr. Andrew T. Chan With 2019 AACR-Waun Ki Hong Award

    Click here to find the press release.

    I received consultant Bayer and Pfizer, Inc.

    I received grant support for investigator-initiated research from:

    • National Institutes of Health
    • National Cancer Institute
    • Crohn’s and Colitis Foundation
    • Bayer AG
    Return to Scientific Advisory Board
    Gaziano

    Mike Gaziano

    Name
    J Michael Gaziano MD, MPH
    Academic Affiliations:

    Professor of Medicine, Harvard Medical School; Chief Division of Aging, Brigham and Women’s Hospital; Director of Preventive Cardiology and Director of Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System.
    Discipline: Cardiology and Epidemiology

    Scientific Interests:
    I am a chronic disease epidemiologist with a particular interest in the roles that individual lifestyle choices (diet, exercise, smoking), metabolic factors (obesity, high cholesterol, and hypertension), and biochemical and genetic markers play on the risk of cardiovascular disease and other chronic illnesses. Also, of interest is the impact that vascular disease has on other organ systems, including cognitive dysfunction and renal disease. I have an interest in the design of large-scale trials and observational studies nested in large health care systems using big data analytic techniques.
    Declaration of Conflicts of Interest:

    I received consultant and speaker fees Bayer.

    I received grant support as a principal investigator or co-investigator for research from the VA, DOD, NIH, Merck and Kowa.

    Return to Scientific Advisory Board
    Pierre A Web Photo

    Pierre Amarenco

    Name

    Pierre Amarenco, MD, FAHA, FAAN

    Academic Affiliations:
    • Professor of Neurology at Paris-Diderot Sorbonne University 
    • Chairman of the Department of Neurology and Stroke Center; Bichat University Hospital
    • Co-Director INSERM Unit-698 “Clinical Research in Atherothrombosis”
    Discipline:

    Neurology and Vascular Neurology

    Scientific Interests:
    • Understanding and preventing stroke and vascular diseases
    • Clinical trials in prevention of vascular diseases
    • Carotid intima-media thickness studies
    • Lipid trials: prevention and therapeutic –protective- evaluation
    Declaration of Conflicts of Interest:

    N/A

    Return to Scientific Advisory Board
    CarloPatrono

    Carlo Patrono

    CHAIR
    Name
    Carlo Patrono MD, FESC, FRCP
    Academic Affiliations:
    Adjunct Professor of Pharmacology at the Catholic University School of Medicine in Rome (Italy) and at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia (USA).
    Discipline:
    Clinical Pharmacology
    Scientific Interests:
    • Studying platelet activation and inhibition in diabetes mellitus
    • Studying platelet activation and inhibition in myeloproliferative neoplasms
    • Investigating the mechanism of action of low-dose aspirin in preventing colorectal cancer
    Declaration of Conflicts of Interest:

    I received consultant and speakers fees from Acticor Biotech,  Amgen,  Bayer, GlaxoSmithKline,  Tremeau,  Zambon.

    I received grant support for investigator-initiated research from:

    • AIFA (Italian Drug Agency)
    • Bayer AG
    • Cancer Research UK
    • European Commission, FP6 and FP7 Programmes

      Return to Scientific Advisory Board

      Have something to say about aspirin?

      We would like to hear from you and have a chat, and maybe feature you on our podcast. Please fill in the form below and we will contact you with further information.

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.